二氢嘧啶脱氢酶突变阴性患者早期5-氟尿嘧啶毒性:尿苷三乙酸酯逆转的临床病程
本文报道一例73岁肛癌患者,在接受标准5-FU化疗后出现严重黏膜炎、极度疲劳及血细胞快速下降,尽管DPD突变检测阴性。在5-FU输注结束后86小时开始使用尿苷三乙酸酯,住院10天内中性粒细胞绝对值恢复正常,黏膜炎显著改善,随访31天无残留症状。
要点
- DPD突变阴性者仍可发生早期5-FU严重毒性,需警惕。
- 尿苷三乙酸酯是5-FU毒性的药理解毒剂,本例在86小时后启用仍有效。
- 治疗后可实现中性粒细胞恢复和黏膜炎显著改善。
核心结论
- DPD突变阴性的患者仍可能发生早期5-FU毒性,尿苷三乙酸酯可逆转此类毒性并改善临床结局。
研究设计与样本
- 个案报道:一例73岁肛癌患者接受标准5-FU化疗和放疗后出现早期毒性,使用尿苷三乙酸酯治疗并随访31天。
主要发现
- 5-FU输注完成后2天出现严重黏膜炎和极度疲劳,随后血细胞计数快速下降和发热。
- 在5-FU输注结束后86小时开始尿苷三乙酸酯治疗,住院10天内中性粒细胞绝对值恢复正常,黏膜炎显著改善。
- 随访31天患者无残留5-FU毒性症状。
关键数值与推荐
- 尿苷三乙酸酯于2015年获FDA批准,是5-FU毒性的口服解毒剂。
- 本例在5-FU输注结束后86小时启动尿苷三乙酸酯治疗。
临床怎么用
- 对接受5-FU治疗的患者,即使DPD突变阴性,也应监测早期毒性表现并及时考虑尿苷三乙酸酯治疗。
局限性
- 为单个病例报告,证据级别有限,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An antimetabolite pyridine analog, 5-fluorouracil (5-FU), is used to treat solid tumors. Early toxicities may occur at standard doses of 5-FU due to dihydropyrimidine dehydrogenase (DPD) deficiency. Uridine triacetate, approved by the Food and Drug Administration in 2015, is an oral prodrug of uridine, a pharmacologic antidote for 5-FU toxicity. To our knowledge, this is the first case report that documents the clinical course of a patient treated with uridine triacetate to reverse early-onset 5-FU toxicity negative for DPD mutations. We describe the case of a 73-year-old man with anal cancer treated with standard-of-care chemotherapy and radiation. Two days after completion of his initial 5-FU infusion, the patient developed severe mucositis and extreme fatigue, followed by a rapid decline in his blood cell counts and fevers. The patient was initiated on uridine triacetate 86 hours after completion of his 5-FU infusion. Over a 10-day hospital length of stay, the patient's absolute neutrophil count recovered to within normal limits, and his mucositis significantly improved. At follow-up visits, the patient denied any residual symptoms of 5-FU toxicity. We describe the patient's clinical course from hospital presentation to 31 days after initiation of uridine triacetate.
引用
- Vaudo CE, Gil B, Galuski K, et al. Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate. Pharmacotherapy. 2016. PMID: 27716991. doi:10.1002/phar.1841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。